RedHill’s Opaganib Gains FDA Rare Pediatric Disease Status
RALEIGH, North Carolina, USA & TEL AVIV, Israel – June 9, 2026 RedHill Biopharma has received a significant regulatory...
AACR 2026
Advertisement
MiNK Advances iNKT Cell Therapy Into Phase 2 Validation
NEW YORK, May 15, 2026 MiNK Therapeutics, Inc. reported first quarter 2026 financial results while highlighting major clinical and...
KUBTEC Launches XCELL TomoRad IGRT Research System
STRATFORD, Conn., May 8, 2026 KUBTEC Scientific has launched the XCELL® TomoRad™ x-ray irradiator, a next-generation image-guided radiotherapy (IGRT)...
Nuvation Bio Expands IBTROZI FDA Lung Cancer Filing
NEW YORK, May 6, 2026 Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food...
Amphista Targeted Glue Data Shows Tumor Regression
CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...
Advertisements
Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer
Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...
Rznomics RZ-001 Shows Strong HCC Clinical Data AACR
SAN DIEGO, Calif., April 19, 2026 Rznomics Inc. announced encouraging interim clinical results from its ongoing study of RZ-001,...
Enara Bio Showcases ENA101 Cancer Immunotherapy at AACR
OXFORD, UK, April 20, 2026 Enara Bio announced the presentation of breakthrough preclinical data for ENA101, its first-in-class bispecific...
Verismo SynKIR-110 Shows Phase 1 Safety in Solid Tumors
PHILADELPHIA, April 20, 2026 Verismo Therapeutics has reported promising initial Phase 1 clinical data from its STAR-101 trial, evaluating...
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
Advertisement
